- Home
- BLNK vs ACIU Comparison
BLNK vs ACIU Comparison
Compare BLNK & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLNK | ACIU |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 213.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BLNK | ACIU |
|---|---|---|
| Price | $0.78 | $2.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $2.13 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 6.4M | 1.4M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,631,000.00 | $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.87 | $738.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $1.43 |
| 52 Week High | $2.65 | $4.00 |
Technical Indicators
Market Signals| Indicator | BLNK | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 26.08 | 47.78 |
| Support Level | $0.77 | $2.54 |
| Resistance Level | $1.43 | $3.45 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 1.85 | 31.75 |
Price Performance
Historical ComparisonAbout BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.